BioTime Inks Progenitor Cell Distribution Deal for China
December 09, 2010 at 12:53 PM EST
BioTime of California has signed up Shanghai Genext Medical Technology as the China marketer of its ACTCellerate™ cell lines, a highly purified source of progenitor cells. Genext will also sell BioTime’s cell cultures, which are customized for each line. ACTCellerate™ is BioTime’s proprietary technology that allows the expansion of over 140 highly-purified primitive human embryonic progenitor cells (hEPCs) from hES or induced pluripotent stem (iPS) cells. More details.... Stock Symbol: (NYSE Amex: BTX)